Increased serum type I interferon activity in early systemic sclerosis patients is associated with antibodies against Sjögren's syndrome antigens and nuclear ribonucleoprotein antigens.
(2013) In Scandinavian Journal of Rheumatology 42(3). p.235-240- Abstract
- Objective: To study serum type I interferon (IFN) activity in patients with early systemic sclerosis (SSc). Method: Serum type I IFN activity was measured in 33 consecutive patients with SSc and a disease duration of < 2 years and in 13 healthy individuals by calculating a type I IFN score according to the induction of six IFN-α regulated genes in a reporter cell line. Results: Twenty-seven per cent of the SSc patients had an increased type I IFN score compared to none of the healthy individuals (p < 0.05). The clinical SSc phenotype associated with high serum type I IFN activity did not differ from patients with low serum type I IFN activity regarding the presence of skin or lung fibrosis, pulmonary hypertension, or digital... (More)
- Objective: To study serum type I interferon (IFN) activity in patients with early systemic sclerosis (SSc). Method: Serum type I IFN activity was measured in 33 consecutive patients with SSc and a disease duration of < 2 years and in 13 healthy individuals by calculating a type I IFN score according to the induction of six IFN-α regulated genes in a reporter cell line. Results: Twenty-seven per cent of the SSc patients had an increased type I IFN score compared to none of the healthy individuals (p < 0.05). The clinical SSc phenotype associated with high serum type I IFN activity did not differ from patients with low serum type I IFN activity regarding the presence of skin or lung fibrosis, pulmonary hypertension, or digital complications. Patients with high serum type I IFN activity were younger (p < 0.01) and had a lower frequency of cardiac involvement (p = 0.053), lower leucocyte count (p < 0.001), higher immunoglobulin (Ig)G levels (p < 0.05), and a higher amount of antibodies against extractable nuclear antigens (p < 0.01) than patients with low serum type I IFN activity. The presence of antibodies against topoisomerase I, Sjögren's syndrome antigen, and nuclear ribonucleoprotein antigens was associated with higher type I IFN activity (p < 0.05 for all comparisons). Conclusions: Our study indicates that increased serum type I IFN activity in early SSc patients is associated with an antibody and laboratory profile that may reflect a subclinical overlap of SSc with other type I IFN-driven connective tissue diseases (CTDs). (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3560236
- author
- Wuttge, Dirk LU ; Lood, Christian LU ; Tufvesson, Ellen LU ; Scheja, Agneta LU ; Truedsson, Lennart LU ; Bengtsson, Anders LU and Hesselstrand, Roger LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Scandinavian Journal of Rheumatology
- volume
- 42
- issue
- 3
- pages
- 235 - 240
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000319036800013
- pmid:23379597
- scopus:84877884719
- pmid:23379597
- ISSN
- 1502-7732
- DOI
- 10.3109/03009742.2012.736532
- language
- English
- LU publication?
- yes
- id
- f23020d5-2d2e-4fef-97ee-71c4ad0d8ab9 (old id 3560236)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23379597?dopt=Abstract
- date added to LUP
- 2016-04-01 10:28:08
- date last changed
- 2022-03-19 21:05:29
@article{f23020d5-2d2e-4fef-97ee-71c4ad0d8ab9, abstract = {{Objective: To study serum type I interferon (IFN) activity in patients with early systemic sclerosis (SSc). Method: Serum type I IFN activity was measured in 33 consecutive patients with SSc and a disease duration of < 2 years and in 13 healthy individuals by calculating a type I IFN score according to the induction of six IFN-α regulated genes in a reporter cell line. Results: Twenty-seven per cent of the SSc patients had an increased type I IFN score compared to none of the healthy individuals (p < 0.05). The clinical SSc phenotype associated with high serum type I IFN activity did not differ from patients with low serum type I IFN activity regarding the presence of skin or lung fibrosis, pulmonary hypertension, or digital complications. Patients with high serum type I IFN activity were younger (p < 0.01) and had a lower frequency of cardiac involvement (p = 0.053), lower leucocyte count (p < 0.001), higher immunoglobulin (Ig)G levels (p < 0.05), and a higher amount of antibodies against extractable nuclear antigens (p < 0.01) than patients with low serum type I IFN activity. The presence of antibodies against topoisomerase I, Sjögren's syndrome antigen, and nuclear ribonucleoprotein antigens was associated with higher type I IFN activity (p < 0.05 for all comparisons). Conclusions: Our study indicates that increased serum type I IFN activity in early SSc patients is associated with an antibody and laboratory profile that may reflect a subclinical overlap of SSc with other type I IFN-driven connective tissue diseases (CTDs).}}, author = {{Wuttge, Dirk and Lood, Christian and Tufvesson, Ellen and Scheja, Agneta and Truedsson, Lennart and Bengtsson, Anders and Hesselstrand, Roger}}, issn = {{1502-7732}}, language = {{eng}}, number = {{3}}, pages = {{235--240}}, publisher = {{Taylor & Francis}}, series = {{Scandinavian Journal of Rheumatology}}, title = {{Increased serum type I interferon activity in early systemic sclerosis patients is associated with antibodies against Sjögren's syndrome antigens and nuclear ribonucleoprotein antigens.}}, url = {{http://dx.doi.org/10.3109/03009742.2012.736532}}, doi = {{10.3109/03009742.2012.736532}}, volume = {{42}}, year = {{2013}}, }